Alnylam Pharmaceuticals (ALNY) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Horizon Therapeutics Public (NASDAQ:HZNP) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.

Do institutionals and insiders hold more shares of ALNY or HZNP?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 80.4% of Horizon Therapeutics Public shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Horizon Therapeutics Public shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has better earnings & valuation, ALNY or HZNP?

Horizon Therapeutics Public has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$1.83B	16.62	-$440.24M	-$2.62	-89.91
Horizon Therapeutics Public	$3.63B	7.34	$521.48M	$1.87	62.19

Do analysts rate ALNY or HZNP?

Alnylam Pharmaceuticals currently has a consensus price target of $294.50, indicating a potential upside of 25.02%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Horizon Therapeutics Public.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.71
Horizon Therapeutics Public	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media favor ALNY or HZNP?

In the previous week, Alnylam Pharmaceuticals had 13 more articles in the media than Horizon Therapeutics Public. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 0 mentions for Horizon Therapeutics Public. Alnylam Pharmaceuticals' average media sentiment score of 0.54 beat Horizon Therapeutics Public's score of 0.00 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Alnylam Pharmaceuticals	Positive
Horizon Therapeutics Public	Neutral

Which has more risk & volatility, ALNY or HZNP?

Alnylam Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Is ALNY or HZNP more profitable?

Horizon Therapeutics Public has a net margin of 12.02% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Horizon Therapeutics Public's return on equity of 20.46% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-15.86%	N/A	-8.38%
Horizon Therapeutics Public	12.02%	20.46%	11.52%

Does the MarketBeat Community believe in ALNY or HZNP?

Alnylam Pharmaceuticals received 171 more outperform votes than Horizon Therapeutics Public when rated by MarketBeat users. However, 79.26% of users gave Horizon Therapeutics Public an outperform vote while only 76.15% of users gave Alnylam Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1130 76.15%	Underperform Votes 354 23.85%
Horizon Therapeutics Public	Outperform Votes 959 79.26%	Underperform Votes 251 20.74%

Summary

Horizon Therapeutics Public beats Alnylam Pharmaceuticals on 10 of the 18 factors compared between the two stocks.